Tags : Initiation


PharmaShots Interview: Rain Therapeutic’s Avanish Vellanki Shares Insight on the

In an interview with PharmaShots, Avanish Vellanki, CEO and Cofounder at Rain Therapeutics shared his views on the initiation of the P-III MANTRA trial to evaluate the safety & efficacy of Milademetan for dedifferentiated liposarcoma and provide updates about the company’s lead candidate, RAIN-32. Shots: The company initiates P-III MANTRA trial to evaluate safety & […]Read More


Otsuka and Click Initiate Digital Study in Adults with Major

Shots: Otsuka and Click have reported the initiation of the Mirai study which is a fully remote clinical trial to investigate the effectiveness of digital therapeutics in reducing depressive symptoms in adults diagnosed with MDD who are on antidepressant monotherapy. The study will enroll ~540 patients globally The trial will run fully remotely utilizing the […]Read More


Samsung Bioepis Reports the Initiation of P-III Study for SB15

Shots: The P-III study will compare the efficacy, safety, PK, and immunogenicity between SB15 and Eylea in 446 patients with neovascular age-related macular degeneration The company has two ophthalmology biosimilar candidates in clinical development, SB11 (ranibizumab) and SB15 (aflibercept). On May 18, 2020, Samsung Bioepis reports 24-week interim results from a P-III study of SB11 […]Read More